Back

Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Young Investigator Award Session Population Sciences Cardiovascular Risk Assessment ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Steven Hageman

University Medical Center Utrecht, Utrecht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Regular exercise after a diagnosis of atrial fibrillation and lower risks of cardiovascular disease: a nationwide population-based study
Doctor H. Ahn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Effect of beta blocker therapy following myocardial infarction in optimally treated patients in the reperfusion era - a Danish, nationwide, and registry-based cohort study
Doctor A. Holt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The association of artificial intelligence-enabled electrocardiogram-derived age (physiologic age) with atherosclerotic cardiovascular events in the community
Doctor J. Medina-Inojosa (Atlanta, US)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session Population Sciences
Video

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
Saving hearts, extending lives: the impact of risk prevention on lifetime estimates in Germany

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources